Preoperative alpha-adrenergic blockade (phenoxybenzamine, before pheochromocytoma/paraganglioma surgery)
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.
Fuente YAML: registro completo
| Componentes | DRUG-PHENOXYBENZAMINE |
|---|
| ID | REG-ALPHA-BLOCKADE-PREOP-PHEO |
|---|---|
| Tipo | Esquema terapéutico |
| Situación | reviewed 2026-07-11 | pending_clinical_signoff |
| Enfermedades | Ninguna declarada |
| Fuentes | SRC-ENDOCRINE-SOCIETY-PPGL-2014 SRC-NCCN-NET-2025 |
Notas
This regimen models the mandatory preoperative alpha-adrenergic blockade step described in the Disease narrative -- NOT a cytotoxic or antineoplastic regimen. It is the recommended_regimen on IND-PHEO-LOCALIZED-1L-ALPHA-BLOCKADE-ADRENALECTOMY and exists purely to prevent intraoperative catecholamine-release hypertensive crisis during adrenalectomy. Adequacy of blockade is gated by RF-PHEO-INADEQUATE-ALPHA-BLOCKADE, a hard hold on proceeding to surgery. No fixed target BP/HR numeric threshold is asserted here -- "adequate" blockade is a clinical judgment per Endocrine Society 2014 guidance, not a KB-invented number. STUB pending clinical co-lead signoff (CHARTER §6.1, dev-mode-exempted).
Utilizado por
Indicación
IND-PHEO-LOCALIZED-1L-ALPHA-BLOCKADE-ADRENALECTOMY- IND-PHEO-LOCALIZED-1L-ALPHA-BLOCKADE-ADRENALECTOMY